Hanmi inks $1.26b licensing deal with Eli Lilly
Hanmi Pharmaceutical said Monday it has clinched an outlicensing contract with Eli Lilly for sonefpeglutide, its long-acting glucagon-like peptide 2, or GLP-2, drug candidate, in a deal potentially worth up to $1.26 billion. According to the Korean drugmaker, it will receive an upfront payment of $75 million and could earn up to $1.19 billion in additional milestone payments depending on clinical development, regulatory approvals and commercialization. Hanmi Pharmaceutical will also be eligible